Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-2,page-paged-2,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • RedHill Biopharma’s Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
    07 September 2021
    www.redhillbio.com
  • Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
    06 September 2021
    www.newron.com
  • Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer
    01 September 2021
    www.avisapharma.com
  • MorphoSys and Incyte Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    26 August 2021
    www.morphosys.com
  • HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX 0215
    10 August 2021
    www.heparegenix.com/
  • InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum
    10 August 2021
    www.inflarx.de
  • InflaRx to Present at the BTIG Virtual Biotechnology Conference
    06 August 2021
    www.inflarx.de
  • Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity
    05 August 2021
    www.secarna.com
  • InflaRx Reports Second Quarter 2021 Financial & Operating Results
    05 August 2021
    www.inflarx.de
  • Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round
    29 July 2021
    www.topas-therapeutics.com